COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation.
暂无分享,去创建一个
M. Metra | S. Curello | A. Petronio | C. Fiorina | M. Adamo | G. Chizzola | L. Branca | E. Chiari | B. Melica | C. Giannini | P. Spontoni | L. Lupi | F. Fiorelli | Renzo D'Ortona | G. Silva | C. Espada Guerreiro
[1] C. Metze,et al. Impact of COAPT trial exclusion criteria in real-world patients undergoing transcatheter mitral valve repair. , 2020, International journal of cardiology.
[2] M. Metra,et al. Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[3] M. Mack,et al. Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation , 2019 .
[4] I. Palacios,et al. Association of Pulmonary Hypertension With Clinical Outcomes of Transcatheter Mitral Valve Repair. , 2019, JAMA cardiology.
[5] A. Íñiguez,et al. The European Registry of MitraClip in Acute Mitral Regurgitation following an acute myocardial infarction (EREMMI). , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[6] D. Maucort-Boulch,et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years , 2019, European journal of heart failure.
[7] B. Prendergast,et al. Mitral regurgitation in heart failure: time for a rethink. , 2019, European heart journal.
[8] D. Capodanno,et al. Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry. , 2019, American heart journal.
[9] O. Alfieri,et al. Treatment of functional mitral regurgitation in chronic heart failure: can we get a ‘proof of concept’ from the MITRA‐FR and COAPT trials? , 2019, European journal of heart failure.
[10] A. Sannino,et al. Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. , 2019, JACC. Cardiovascular imaging.
[11] M. Metra,et al. Left ventricular reverse remodelling predicts long‐term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry , 2018, European journal of heart failure.
[12] O. Alfieri,et al. Mid‐term outcomes (up to 5 years) of percutaneous edge‐to‐edge mitral repair in the real‐world according to regurgitation mechanism: A single‐center experience , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[13] M. Mack,et al. Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial , 2018, American heart journal.
[14] M. Mack,et al. Transcatheter Mitral‐Valve Repair in Patients with Heart Failure , 2018, The New England journal of medicine.
[15] D. Maucort-Boulch,et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.
[16] J. Mascherbauer,et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure , 2017, European heart journal.
[17] Jeroen J. Bax,et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. , 2017, European heart journal.
[18] L. Fleisher,et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.
[19] M. Metra,et al. Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience. , 2017, International journal of cardiology.
[20] H. Schunkert,et al. Predictors for long‐term survival after transcatheter edge‐to‐edge mitral valve repair , 2017, Journal of interventional cardiology.
[21] M. Neuss,et al. Role of Right Ventricular Dysfunction and Diabetes Mellitus in N-terminal pro-B-type Natriuretic Peptide Response of Patients With Severe Mitral Regurgitation and Heart Failure After MitraClip. , 2017, International heart journal.
[22] C. Rapezzi,et al. Percutaneous mitral valve repair: The last chance for symptoms improvement in advanced refractory chronic heart failure? , 2017, International journal of cardiology.
[23] A. Colombo,et al. Right ventricular evaluation to improve survival outcome in patients with severe functional mitral regurgitation and advanced heart failure undergoing MitraClip therapy. , 2016, International journal of cardiology.
[24] P. Boekstegers,et al. Predictors for short-term outcomes of patients undergoing transcatheter mitral valve interventions: analysis of 778 prospective patients from the German TRAMI registry focusing on baseline renal function. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[25] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[26] P. Boekstegers,et al. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry , 2015, European heart journal.
[27] G. Filippatos,et al. Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. , 2015, Journal of the American College of Cardiology.
[28] D. Capodanno,et al. Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair. , 2015, American heart journal.
[29] J. Tijssen,et al. Predictors of outcome in patients undergoing MitraClip implantation: An aid to improve patient selection. , 2015, International journal of cardiology.
[30] M. Metra,et al. Effectiveness of MitraClip therapy in patients with refractory heart failure. , 2015, Journal of interventional cardiology.
[31] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[32] D. Capodanno,et al. Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. , 2014, European heart journal cardiovascular Imaging.
[33] S. Blankenberg,et al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. , 2014, Journal of the American College of Cardiology.
[34] J. Hausleiter,et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. , 2013, Journal of the American College of Cardiology.
[35] M. Neuss,et al. Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regurgitation and severe congestive heart failure , 2013, European journal of heart failure.
[36] A. Branzi,et al. Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long‐term outcome study , 2010, European journal of heart failure.